©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
A Novel Cobra Venom Metalloproteinase, Mocarhagin, Cleaves a 10-Amino Acid Peptide from the Mature N Terminus of P-selectin Glycoprotein Ligand Receptor, PSGL-1, and Abolishes P-selectin Binding (*)

(Received for publication, August 21, 1995; and in revised form, September 11, 1995)

Mariagrazia De Luca (1) Lindsay C. Dunlop (1) Robert K. Andrews (1) John V. Flannery , Jr. (2) Rebecca Ettling (2) Dale A. Cumming (2) Geertruida M. Veldman (2) Michael C. Berndt (1)(§)

From the  (1)Vascular Biology Laboratory, Baker Medical Research Institute, Commercial Road, Prahran, Victoria 3181, Australia and the (2)Small Molecule Drug Discovery Group, Genetics Institute, Cambridge, Massachusetts 02140

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

Initial rolling of circulating neutrophils on a blood vessel wall prior to adhesion and transmigration to damaged tissue is dependent upon P-selectin expressed on endothelial cells and its specific neutrophil receptor, the P-selectin glycoprotein ligand-1 (PSGL-1). Pretreatment of neutrophils, HL60 cells, or a recombinant fucosylated soluble form of PSGL-1 (sPSGL-1.T7) with the cobra venom metalloproteinase, mocarhagin, completely abolished binding to purified P-selectin in a time-dependent and EDTA- and diisopropyl fluorophosphate-inhibitable manner consistent with mocarhagin selectively cleaving PSGL-1. A polyclonal antibody against the N-terminal peptide Gln-1-Glu-15 of mature PSGL-1 immunoprecipitated sPSGL-1.T7 but not sPSGL-1.T7 treated with mocarhagin, indicating that the mocarhagin cleavage site was near the N terminus. A single mocarhagin cleavage site between Tyr-10 and Asp-11 of mature PSGL-1 was determined by N-terminal sequencing of mocarhagin fragments of sPSGL-1.T7 and is within a highly negatively charged amino acid sequence 1-QATEYEYLDYDFLPETEPPE, containing three tyrosine residues that are consensus sulfation sites. Consistent with a functional role of this region of PSGL-1 in binding P-selectin, an affinity-purified polyclonal antibody against residues Gln-1-Glu-15 of PSGL-1 strongly inhibited P-selectin binding to neutrophils, whereas an antibody against residues Asp-9-Arg-23 was noninhibitory. These combined data strongly suggest that the N-terminal anionic/sulfated tyrosine motif of PSGL-1 as well as downstream sialylated carbohydrate is essential for binding of P-selectin by neutrophils.


INTRODUCTION

In response to inflammatory stimuli, neutrophils in the adjacent vasculature initially roll on the blood vessel wall, then stick, and finally transmigrate to the site of insult(1) . The initial rolling event involves a class of adhesion proteins termed selectins (P-, E-, and L-selectin), which mediate the interaction between leukocytes and endothelial cells by recognizing specific carbohydrate counterstructures, including sialyl-Lewis x(2, 3, 4) . P-selectin binds to 10,000-20,000 copies of a single class of binding site on neutrophils and HL60 cells(4, 5) . Studies in a number of laboratories have identified a 220-240-kDa, disulfide-linked homodimeric protein, which appears to specifically bind P-selectin(6, 7) . This protein is probably identical to P-selectin glycoprotein ligand-1 (PSGL-1)(^1)(8) . PSGL-1 is a 220-kDa, disulfide-linked homodimeric sialomucin, which, when expressed in COS cells with the appropriate fucosyltransferase, binds P-selectin in a similar calcium-dependent manner to the receptor on neutrophils. PSGL-1 has a signal peptide sequence of 17 amino acids followed by a 24-amino acid PACE propeptide sequence(8) . The mature N terminus of PSGL-1 contains an unusual stretch of 20 amino acids, which is rich in negatively charged aspartate and glutamate residues and which contains three tyrosine residues that meet the consensus sequence for O-sulfation by Golgi sulfotransferase(s)(9) . At least one of these tyrosine residues is sulfated as evaluated by site-directed mutagenesis and sulfate labeling experiments. (^2)

PSGL-1 also binds E-selectin. In contrast to P-selectin, however, the requirements for E-selectin recognition are much less rigid. E-selectin binds a number of sialomucin and glycoprotein structures if they co-express the sialyl-Lewis x structure(8, 10) . L-selectin binds to a number of different counter-receptors, glycoprotein cell adhesion molecule-1, mucosal addressin cell adhesion molecule-1, and CD34, which, like PSGL-1, are also sialomucins(11) . A major question currently unresolved is what determines selectin specificity in the recognition of specific counter-receptor structures. P-, E-, and L-selectin are 60-70% homologous in their N-terminal, lectin motifs, and each similarly recognizes the sialyl-Lewis x and sialyl-Lewis a carbohydrate structures(11, 12) . Further, binding of P-selectin to its receptor on neutrophils is 4-5 orders of magnitude more avid than the binding to sialyl-Lewis x(4, 5, 11, 13) . While differences in specificity and avidity may in part be accounted for either by the presentation of multiple sialyl-Lewis carbohydrate structures on the receptor mucin core or by subtle differences in carbohydrate structure, it is clear that the protein component of the sialomucin also plays a critical role in selectin interaction(8, 14) .

In the present paper, we describe a highly specific metalloproteinase, mocarhagin, which has been purified from the venom of the Mozambiquan spitting cobra, Naja mocambique mocambique. Mocarhagin cleaves a 10-amino acid peptide from the mature N terminus of PSGL-1 and abolishes the ability of PSGL-1 to bind P-selectin. The results are in accord with the negative charge/sulfated tyrosine cluster at the N terminus of PSGL-1 being an important determinant of P-selectin recognition in addition to its recognition of carbohydrate structure.


EXPERIMENTAL PROCEDURES

Materials

N. mocambique mocambique venom, diisopropyl fluorophosphate (DFP), aprotinin, and pepstatin were purchased from Sigma; Triton X-100 from BDH, Kilsyth, Victoria, Australia; RPMI tissue culture medium from Flow Laboratories, Irvine, Scotland; fetal bovine serum from Cytosystems, Castle Hill, N.S.W., Australia; heparin-Sepharose CL-6B, protein A-Sepharose, and Sepharose CL-6B from Pharmacia, Uppsala, Sweden; leupeptin from Auspep, Melbourne, Victoria, Australia. Sodium [I]iodide and sodium [^3H]borohydride were from DuPont NEN. The PSGL-1 peptide, Thr-3 to Glu-17, was synthesized by Chiron, Melbourne, Australia. Synthetic peptides based on the PSGL-1 sequences Gln-1 to Glu-15 and Asp-9 to Arg-23 (Chiron) containing an N-terminal cysteine residue were coupled to keyhole limpet hemocyanin (Sigma) with m-maleimidobenzoyl-N-hydroxysuccinimide (Pierce), and rabbit antisera were raised and affinity-purified as described previously(15) . Non-immune rabbit IgG was also prepared as described previously(5) .

Purification of Mocarhagin

The purification and characterization of mocarhagin, a 55-kDa cobra venom metalloproteinase, is to be published elsewhere. (^3)Briefly, mocarhagin was purified from crude venom of the snake, N. mocambique mocambique, based on its heparin binding properties. Crude lyophilized venom (0.5 g) was dissolved in water (10 ml) and loaded onto a heparin-Sepharose CL-6B column (1.5 times 40 cm) at 25 ml/h. Following washing with column buffer containing 0.01 M Tris, 0.15 M sodium chloride, pH 7.4 (TS buffer), bound protein was eluted with a linear 250-ml, 0.15-1.0 M sodium chloride gradient in 0.01 M Tris, pH 7.4. Fractions containing mocarhagin, as assessed by SDS-polyacrylamide gel electrophoresis, were pooled and concentrated in an Amicon ultrafiltration device and then loaded at 25 ml/h onto a Sepharose CL-6B column (1.5 times 70 cm). Peak eluted fractions were dialyzed against TS buffer. DFP-treated mocarhagin was prepared by treating mocarhagin (250 µg/ml) in TS buffer with 8 mM DFP for 1 h at 22 °C, followed by extensive dialysis against the same buffer.

Binding of P-selectin to Neutrophils and HL60 Cells

Binding of I-labeled P-selectin to freshly isolated neutrophils and HL60 cells was performed as described previously in detail(5) . To examine the effect of pretreatment of neutrophils or HL60 cells with mocarhagin on P-selectin binding, washed cells (2 times 10^7/ml) in RPMI made 1% in fetal bovine serum were incubated in the presence or absence of 10 mM EDTA followed by mocarhagin (0.025-100 µg/ml, final concentration) for 30 min at 22 °C. P-selectin binding was then assessed either directly or after the cells were centrifuged, washed twice, and resuspended in RPMI with 1% fetal bovine serum. In some experiments, DFP-treated mocarhagin was employed in place of mocarhagin. To evaluate the effect of supernatant from mocarhagin-treated cells on P-selectin binding, HL60 cells at 10^8/ml in 0.01 M Tris, 0.15 M sodium chloride, 0.001 M calcium chloride, pH 7.4, were incubated with mocarhagin (12 µg/ml) for 10 min at 22 °C. The supernatant collected following centrifugation at 1,000 times g for 10 min was made 0.1% in BSA and loaded onto a heparin-Sepharose CL-6B column (0.5 times 5 cm) to remove mocarhagin. The flow-through was then tested for its effect on P-selectin binding to HL60 cells. The effect of anti-PSGL-1 peptide antibodies on P-selectin binding was evaluated by incubating washed neutrophils with antibody for 20 min at 22 °C prior to the addition of I-labeled P-selectin. In additional control experiments, PSGL-1 peptides (100 µM, final concentration) were mixed with anti-PSGL-1 peptide antibody (100 µg/ml, final concentration) prior to addition to the neutrophils.

Effect of Mocarhagin on Surface-labeled Neutrophils and HL60 Cells

Washed neutrophils or HL60 cells were surface labeled either by lactoperoxidase-catalyzed radioiodination or with sodium periodate/sodium [^3H]borohydride(16, 17) . Labeled cells in 0.01 M Tris, 0.15 M sodium chloride, 1 mM calcium chloride, pH 7.4, were incubated with mocarhagin (12 µg/ml, final concentration) or buffer for 10 min at 22 °C. The cells were centrifuged at 150 times g for 10 min and washed twice with 0.01 M Hepes, 0.15 M sodium chloride, 0.001 M EDTA, pH 7.4. The cells were then lysed with 1% (v/v) Triton X-100 at 4 °C for 1 h in the presence of the following protease inhibitors: DFP (0.5 mM), aprotinin (10 µg/ml), pepstatin (1 µM), leupeptin (100 µg/ml), and benzamidine (10 mM). The Triton X-100 soluble fractions separated by centrifugation at 1,000 times g for 10 min and the supernatants from the control and mocarhagin-treated cells were mixed with SDS sample buffer and electrophoresed on a 5-15% SDS-polyacrylamide gel under reducing and non-reducing conditions or on a two-dimensional non-reduced/reduced gel as described by Phillips and Agin(18) .

Mocarhagin Digestion of Soluble PSGL-1

COS cells were cotransfected with three plasmids encoding soluble PSGL-1 (pED.sPSGL-1.T7)(8) , alpha-1,3/1,4-fucosyltransferase (pEA.3/4FT), and soluble PACE (pEA-PACE SOL)(19) . [S]Methionine-labeled COS conditioned medium containing sPSGL-1.T7 was digested with 5 µg/ml mocarhagin in TS buffer containing 2 mM calcium chloride, 1 mg/ml BSA for 20 min at 37 °C. The ability of sPSGL-1.T7 to bind P-selectin was assessed by precipitation with the P-selectin IgG chimera LEC1 (8) preabsorbed onto protein A-Sepharose beads in TS buffer, 2 mM calcium chloride, 1 mg/ml BSA for 4 h at 4 °C. A control experiment was also performed where the LEC1 protein A-Sepharose beads were pretreated with mocarhagin and then exhaustively washed prior to presentation of sPSGL-1.T7. For immunoprecipitation analysis of untreated and mocarhagin-treated sPSGL-1.T7, the protease was inactivated by the addition of 5 mM EDTA. sPSGL-1.T7 was then immunoprecipitated with anti-PSGL-1 polyclonal antibodies, Rb3026, raised against COS-produced sPSGL-1.T7 (8) or Rb3443-raised against the N-terminal peptide of PACE-cleaved PSGL-1 (Gln-1 to Glu-15).

Identification of the Cleavage Site for Mocarhagin on PSGL-1

Purified sPSGL-1.T7 (20 µg) was digested with 1 µg of mocarhagin in a total volume of 100 µl of TS buffer containing 2 mM calcium chloride for 1 h at 37 °C. The protease was inactivated by addition of 10 mM EDTA. The sample was concentrated directly onto Pro-spin (Applied Biosystems, Foster City, CA) and subjected to N-terminal sequencing on an ABI M476 gas phase protein sequencer. The synthetic peptide corresponding to residues 3-17 of mature PSGL-1 was dissolved at 0.3 mg/ml in 50 mM Hepes saline buffer, pH 7.4, made 1 mM in calcium chloride, and digested with 10 µg/ml mocarhagin for 1 h. After reverse-phase HPLC separation of the reaction products, N-terminal sequence analysis was performed with an Applied Biosystems model 470A protein sequencer.


RESULTS AND DISCUSSION

We have recently identified and purified a novel metalloproteinase, mocarhagin, from the venom of the Mozambiquan spitting cobra, N. mocambique mocambique. The proteinase requires either calcium ion or zinc ion for activity and is fully inhibited by excess EDTA and by high concentrations of DFP. Pretreatment of platelets with mocarhagin abolishes their ability to bind the adhesive ligand, von Willebrand Factor. This is due to proteolysis between Glu-282 and Asp-283, DEGDTDLYDYYPEEDTEGD, in the alpha-chain of the platelet GP Ib-V-IX complex, which occurs as the sole detectable cleavage on the intact platelet surface.^3

In the course of these studies, we observed that mocarhagin was also a potent inhibitor of P-selectin binding to its myeloid receptor on neutrophils. Pretreatment of either neutrophils or HL60 cells with mocarhagin profoundly and reproducibly affected the subsequent binding of P-selectin to these treated cells with an apparent IC of 0.1 µg/ml. A representative inhibition curve from multiple studies is shown in Fig. 1. Equivalent data were obtained regardless of whether the mocarhagin-treated cells were washed or not washed prior to the addition of P-selectin. Further, inhibition was not reversed by incubation of the treated cells with fresh medium for up to 3 h. Finally, mocarhagin had no apparent effect on the molecular size of P-selectin or on its inherent ability to bind to myeloid cells (data not shown and see Fig. 2). Treatment of mocarhagin with DFP completely blocked its ability to inhibit P-selectin binding even at 100 µg/ml (Fig. 1), a result in accord with proteolysis of the P-selectin receptor. Consistent with this view, the ability of mocarhagin to inhibit subsequent P-selectin binding was divalent cation- and time-dependent. If cells were incubated with 12 µg/ml mocarhagin for 10 s prior to the addition of EDTA and the cells then washed, P-selectin binding was reduced, even with this brief treatment, to 40% of normal (data not shown). Cell surface labeling studies, however, failed to identify a major substrate for mocarhagin on either neutrophils or HL60 cells (data not shown), a finding consistent with the exquisite substrate specificity of mocarhagin suggested by the platelet studies. In addition, the concentrated supernatant from mocarhagin-treated cells, after removal of mocarhagin by absorption with heparin-Sepharose CL-6B, did not inhibit binding of P-selectin to HL60 cells, indicating that a functional fragment of the P-selectin receptor was not released by mocarhagin treatment.


Figure 1: Effect of mocarhagin on P-selectin binding to neutrophils. Neutrophils were pretreated for 30 min at room temperature with increasing concentrations of mocarhagin (circles) or with mocarhagin that had been treated with DFP (triangles).




Figure 2: Mocarhagin digestion of soluble P-selectin glycoprotein ligand. COS-conditioned medium containing [S]methionine-labeled sPSGL-1.T7 was untreated (lanes 1, 3, 5, 6, and 8) or digested with 5 µg/ml mocarhagin (lanes 2, 4, 7, and 9). The samples were either directly electrophoresed (lanes 1 and 2) or precipitated with the P-selectin IgG chimera LEC1 (lanes 3 and 4) or precipitated with LEC1, which was pretreated with mocarhagin (LEC1 + mo; lane 5), or immunoprecipitated with Rb3026 (lanes 6 and 7) or with Rb3443 (lanes 8 and 9).



PSGL-1 has recently been identified as a functional ligand for P-selectin on HL60 cells(8) . A soluble form of PSGL-1 (sPSGL-1.T7) expressed in COS cells with an alpha-1,3/1,4-fucosyltransferase also mediates P-selectin binding in a calcium-dependent manner (8) . One of the striking features of PSGL-1 is its similarity to the alpha-chain of platelet GP Ib. Both are sialomucins and each has immediately N-terminal to the mucin core a sequence rich in negatively charged amino acids with three potential sulfated tyrosine residues(8, 20, 21, 22) . Since mocarhagin cleaves the alpha-chain of GP Ib within this negative charge/sulfated tyrosine cluster (see above), we speculated that mocarhagin may abrogate P-selectin binding to neutrophils and HL60 cells by cleaving near the N terminus of PSGL-1, a result that would explain the failure to identify a major substrate for mocarhagin on myeloid cells. That this is indeed the case is confirmed by the data in Fig. 2. Mocarhagin digestion of PACE-cleaved, fucosylated sPSGL-1.T7 resulted in only a minor shift, if any, in electrophoretic mobility of the protein on a SDS-polyacrylamide gel (lanes 1 and 2) but completely abolished the binding of sPSGL-1.T7 to the P-selectin IgG chimera, LEC1(8) , coupled to protein A-Sepharose (lanes 3 and 4). To exclude the possibility that the protease treatment interfered with LEC1 binding by destroying the LEC1 protein A-Sepharose complex, LEC1-protein A-Sepharose beads were incubated with mocarhagin and then washed repeatedly to remove any residual protease. The protease-treated beads were unaffected in their ability to bind sPSGL-1.T7 (lane 5). Fig. 2also shows the reactivity of untreated and mocarhagin-digested sPSGL-1.T7 with two polyclonal antibodies. Rb3026(17) , which was raised against COS-produced sPSGL-1.T7, precipitated sPSGL-1 independent of mocarhagin digestion (lanes 6 and 7), whereas Rb3443, which was raised against the N-terminal peptide of PACE-cleaved PSGL-1 (QATEYEYLDYDFLPE), only precipitated untreated sPSGL-1.T7 (lanes 8 and 9), indicating that the N-terminal epitope for Rb3443 is lost after mocarhagin digestion.

N-terminal microsequencing of purified, mocarhagin-treated sPSGL-1.T7 protein gave the sequence, DFLPETEPPEML. Mocarhagin thus removes the first 10 amino acids from PACE-cleaved sPSGL-1.T7. The site of cleavage for mocarhagin between Tyr-10 and Asp-11 was confirmed using the synthetic peptide, TEYEYLDYDFLPETE, corresponding to residues 3-17 of mature PSGL-1. The mocarhagin cleavage sites on PSGL-1 and the alpha-chain of GP Ib are similar. Each occurs on the N-terminal site of an aspartate residue and to the C-terminal side of three potential sulfated tyrosine residues (8, 22) and within an overall negative charge cluster. Since the proteolytic activity of mocarhagin is inhibited by heparin,^3 this preference for negative charge cluster may in part explain the remarkable substrate specificity of mocarhagin.

Confirmation of the critical importance of the N-terminal sequence of PSGL-1 in P-selectin binding was obtained using anti-peptide antibodies. P-selectin binding to neutrophils was inhibited by 80-90% by an affinity-purified polyclonal antibody against residues Gln-1 to Glu-15 of mature PSGL-1 (QATEYEYLDYDFLPE) but not by an affinity-purified polyclonal antibody against residues Asp-9 to Arg-23 (DYDFLPETEPPEMLR) (Fig. 3) or by non-immune rabbit IgG (not shown). Inhibition by the anti-peptide antibody against Gln-1 to Glu-15 was completely blocked by the presence of either the Gln-1 to Glu-15 or Asp-9 to Arg-23 peptides (data not shown), indicating that anti-peptide antibody, at least in part, recognizes the sequence, Asp-9 to Glu-15.


Figure 3: Effect of anti-PSGL-1 IgG on P-selectin binding to neutrophils. Dose-response curves for inhibition of specific binding of I-P-selectin to neutrophils by polyclonal IgG against synthetic peptide sequences Gln-1 to Glu-15 (circles) and Asp-9 to Arg-23 (squares). Data are representative of at least three experiments with different donor neutrophils.



Although P-, E-, and L-selectins all recognize similar sialylated carbohydrate structures such as sialyl-Lewis x (11) and many glycoproteins on the surface of myeloid cells contain sialyl-Lewis x (23, 24) , P-selectin appears to be highly specific in its recognition of PSGL-1. The present data suggest that one cause for this specificity is the negative charge/sulfated tyrosine cluster at the N terminus of mature PSGL-1. Proteolytic removal of a N-terminal 10-amino acid peptide by mocarhagin abolished P-selectin binding to PSGL-1 even though this sequence (QATEYEYLDY) is not glycosylated. One explanation for this phenomenon is that removal of this sequence alters the conformational integrity of PSGL-1 such that P-selectin can no longer interact with critical carbohydrate structures associated with the PSGL-1 mucin core. This is unlikely for two reasons. First, an affinity-purified polyclonal antibody against the N-terminal 15 amino acids of mature PSGL-1 also strongly inhibited P-selectin binding to neutrophils. Second, E-selectin also binds to PSGL-1(8, 25, 26) , but, unlike P-selectin, E-selectin binds equally well to mocarhagin-cleaved PSGL-1 (data not shown), suggesting that the carbohydrate recognition structures on PSGL-1 are still inherently accessible. An alternative explanation of the present observations is that P-selectin binding to PSGL-1 is bimodal with P-selectin binding not only involving carbohydrate recognition but also the negative charge/sulfated tyrosine cluster. The approximately 4 order of magnitude difference in avidity for P-selectin binding to sialyl-Lewis x versus receptor (11) is strongly suggestive that additional structural determinants are involved in binding of P-selectin to its myeloid receptor. This is supported by the observation that P-selectin binding to myeloid cells not only depends on the N-terminal lectin domain but also involves the adjacent epidermal growth factor-like motif(27) . We, and subsequently others, have demonstrated that P-selectin binds to heparin and to a wide variety of other sulfated glycans and polyanionic structures(5, 28) . It is tempting to speculate that the N-terminal negative charge/sulfated tyrosine cluster of PSGL-1 represents an equivalent polyanionic recognition site and that the juxtaposition of this sequence with appropriate sialylated carbohydrate structure explains the specificity of P-selectin recognition.


FOOTNOTES

*
This work was supported by the National Health and Medical Research Council of Australia. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: Vascular Biology Laboratory, Baker Medical Research Inst., Commercial Rd., Prahran, Victoria 3181, Australia. Tel.: 61 3 522 4333; Fax: 61 3 521 1362.

(^1)
The abbreviations used are: PSGL-1, P-selectin glycoprotein ligand-1; sPSGL-1, soluble P-selectin glycoprotein ligand-1; DFP, diisopropyl fluorophosphate; PACE, paired basic amino acid cleaving enzyme; BSA, bovine serum albumin; GP, glycoprotein.

(^2)
D. Sako, K. M. Comess, K. Barone, R. T. Camphausen, D. A. Cumming, and G. D. Shaw, submitted for publication.

(^3)
C. M. Ward, R. K. Andrews, A. I. Smith, and M. C. Berndt, manuscript in preparation.


ACKNOWLEDGEMENTS

It is a pleasure to thank Julie Simpson for assistance in manuscript preparation.


REFERENCES

  1. Butcher, E. C. (1991) Cell 67, 1033-1036 [Medline] [Order article via Infotrieve]
  2. Polley, M. J., Phillips, M. L., Wayner, E., Nudelman, E., Singhal, A. K., Hakomori, S.-I., and Paulson, J. C. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 6224-6228 [Abstract]
  3. Phillips, M. L., Nudelman, E., Gaeta, F. C. A., Perez, M., Singhal, A. K., Hakomori, S.-I., and Paulson, J. C. (1990) Science 250, 1130-1132 [Medline] [Order article via Infotrieve]
  4. Moore, K. L., Varki, A., and McEver, R. P. (1991) J. Cell Biol. 112, 491-499 [Abstract]
  5. Skinner, M. P., Lucas, C. P., Burns, G. F., Chesterman, C. N., and Berndt, M. C. (1991) J. Biol. Chem. 266, 5371-5374 [Abstract/Free Full Text]
  6. Moore, K. L., Stults, N. L., Diaz, S., Smith, D. F., Cummings, R. D., Varki, A., and McEver, R. P. (1992) J. Cell Biol. 118, 445-456 [Abstract]
  7. Norgard, K. E., Moore, K. L., Diaz, S., Stults, N. L., Ushiyama, S., McEver, R. P., Cummings, R. D., and Varki, A. (1993) J. Biol. Chem. 268, 12764-12774 [Abstract/Free Full Text]
  8. Sako, D., Chang, X.-J., Barone, K. M., Vachino, G., White, H. M., Shaw, G., Veldman, G. M., Bean, K. M., Ahem, T. J., Furie, B., Cumming, D. A., and Larsen, G. R. (1993) Cell 75, 1179-1186 [Medline] [Order article via Infotrieve]
  9. Huttner, W. B. (1988) Annu. Rev. Physiol. 50, 363-376 [CrossRef][Medline] [Order article via Infotrieve]
  10. Levinovitz, A., Mühlhoff, J., Isenmann, S., and Vestweber, D. (1993) J. Cell Biol. 121, 449-459 [Abstract]
  11. McEver, R. P., Moore, K. L., and Cummings, R. D. (1995) J. Biol. Chem. 270, 11025-11028 [Abstract/Free Full Text]
  12. Varki, A. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 7390-7397 [Abstract]
  13. Nelson, R. M., Dolich, S., Aruffo, A., Cecconi, O., and Bevilacqua, M. P. (1993) J. Clin. Invest. 91, 1157-1166 [Medline] [Order article via Infotrieve]
  14. Larsen, G. R., Sako, D., Ahern, T. J., Shaffer, M., Erban, J., Sajer, S. A., Gibson, R. M., Wagner, D. D., Furie, B. C., and Furie, B. (1992) J. Biol. Chem. 267, 11104-11110 [Abstract/Free Full Text]
  15. Chong, B. H., Murray, B., Berndt, M. C., Dunlop, L. C., Brighton, T., and Chesterman, C. N. (1994) Blood 83, 1535-1541 [Abstract/Free Full Text]
  16. Booth, W., Berndt, M. C., and Castaldi, P. A. (1984) J. Clin. Invest. 73, 291-297 [Medline] [Order article via Infotrieve]
  17. Berndt, M. C., and Phillips, D. R. (1981) J. Biol. Chem. 256, 59-65 [Abstract/Free Full Text]
  18. Phillips, D. R., and Agin, P. P. (1977) J. Biol. Chem. 252, 2121-2126 [Medline] [Order article via Infotrieve]
  19. Wasley, L. C., Rehemtulla, A., Bristol, J. A., and Kaufman, R. J. (1993) J. Biol. Chem. 268, 8458-8465 [Abstract/Free Full Text]
  20. Lopez, J. A., Chung, D. W., Fujikawa, K., Hagen, F. S., Papayannopoulou, T., and Roth, G. J. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 5615-5619 [Abstract]
  21. Titani, K., Takio, K., Handa, M., and Ruggeri, Z. M. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 5610-5614 [Abstract]
  22. Dong, J.-F., Li, C. Q., and López, J. A. (1994) Biochemistry 33, 13946-13953 [Medline] [Order article via Infotrieve]
  23. Lee, N., Wang, W.-C., and Fukuda, M. (1990) J. Biol. Chem. 265, 20476-20487 [Abstract/Free Full Text]
  24. Fukuda, M., Spooncer, E., Oates, J. E., Dell, A., and Klock, J. C. (1984) J. Biol. Chem. 259, 10925-10935 [Abstract/Free Full Text]
  25. Moore, K. L., Eaton, S. F., Lyons, D. E., Lichenstein, H. S., Cummings, R. D., and McEver, R. P. (1994) J. Biol. Chem. 269, 23318-23327 [Abstract/Free Full Text]
  26. Asa, D., Raycroft, L., Ma, L., Aeed, P. A., Kaytes, P. S., Elhammer, Å. P., and Geng, J.-G. (1995) J. Biol. Chem. 270, 11662-11670 [Abstract/Free Full Text]
  27. Kansas, G. S., Saunders, K. B., Ley, K., Zakrzewicz, A., Gibson, R. M., Furie, B. C., Furie, B., and Tedder, T. F. (1994) J. Cell Biol. 124, 609-618 [Abstract]
  28. Aruffo, A., Kolanus, W., Walz, G., Fredman, P., and Seed, B. (1991) Cell 67, 35-44 [Medline] [Order article via Infotrieve]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.